Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.

Timeline

Start

2024-04-10

Primary completion

2026-01-22

Completion

2026-02-20

Outcome

Met primary endpoint

paper estimated treatment differences versus placebo of -0·88% (95% CI -1·18 to -0·59) with retatrutide 4 mg PMID 42250575 ↗

release “In TRANSCEND-T2D-1, retatrutide met the primary and all key secondary endpoints at 40 weeks in adults with type 2 diabetes” lilly.com ↗

Publications

• Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026 Jun 13;407(10546):2402-2413. doi: 10.1016/S0140-6736(26)00967-0. Epub 2026 Jun 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Retatrutide	Protein / enzyme biologic	4 mg	Subcutaneous
Subject	Retatrutide	Protein / enzyme biologic	9 mg	Subcutaneous
Subject	Retatrutide	Protein / enzyme biologic	12 mg	Subcutaneous

Indications